• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.

作者信息

Roblin Xavier, Paul Stéphane, Ben-Horin Shomron

机构信息

Department of Gastroenterology and Immunology, University Hospital of Saint Etienne, Saint Etienne, France.

Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

出版信息

J Crohns Colitis. 2018 Feb 28;12(3):379-380. doi: 10.1093/ecco-jcc/jjx142.

DOI:10.1093/ecco-jcc/jjx142
PMID:29088342
Abstract
摘要

相似文献

1
Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.戈利木单抗和维多珠单抗联合治疗重度溃疡性结肠炎及相关脊柱关节病
J Crohns Colitis. 2018 Feb 28;12(3):379-380. doi: 10.1093/ecco-jcc/jjx142.
2
Complete reversal of nephrotic syndrome secondary to amyloidosis with use of infliximab in a patient with inflammatory bowel disease and ankylosing spondylitis.英夫利昔单抗治疗炎症性肠病和强直性脊柱炎伴发淀粉样变性肾病综合征的完全缓解。
Ren Fail. 2011;33(5):531-3. doi: 10.3109/0886022X.2011.577543.
3
Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab.氨基水杨酸盐的联合使用与溃疡性结肠炎患者升级为维得利珠单抗后改善结局无关。
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2374-2376.e2. doi: 10.1016/j.cgh.2018.11.062. Epub 2018 Dec 7.
4
Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.使用维多珠单抗治疗一名溃疡性结肠炎患者的重症Sweet综合征。
J Crohns Colitis. 2018 Aug 29;12(9):1134-1135. doi: 10.1093/ecco-jcc/jjy066.
5
Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.维多珠单抗治疗与改善炎症性肠病患者的睡眠质量和情绪有关。
Dig Dis Sci. 2017 Jan;62(1):197-206. doi: 10.1007/s10620-016-4356-2. Epub 2016 Oct 28.
6
Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.英夫利昔单抗、阿达木单抗、戈利木单抗和维多珠单抗用于西班牙中重度溃疡性结肠炎的成本效益分析
Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3):321-329. doi: 10.1080/14737167.2018.1411193. Epub 2017 Dec 2.
7
Positioning Therapy for Ulcerative Colitis.溃疡性结肠炎的定位治疗
Curr Gastroenterol Rep. 2015 Aug;17(8):29. doi: 10.1007/s11894-015-0454-0.
8
Recent trends and future directions for the medical treatment of ulcerative colitis.溃疡性结肠炎医学治疗的近期趋势与未来方向
Clin J Gastroenterol. 2016 Dec;9(6):329-336. doi: 10.1007/s12328-016-0686-z. Epub 2016 Oct 3.
9
Should we use vedolizumab as mono or combo therapy in ulcerative colitis?我们应该在溃疡性结肠炎中使用维得利珠单抗单药治疗还是联合治疗？
Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:27-34. doi: 10.1016/j.bpg.2018.05.002. Epub 2018 May 12.
10
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.一项在溃疡性结肠炎患者中比较维得利珠单抗、阿达木单抗和古利昔单抗的倾向评分加权比较。
Dig Liver Dis. 2020 Dec;52(12):1461-1466. doi: 10.1016/j.dld.2020.06.014. Epub 2020 Jun 26.

引用本文的文献

1
Dual anti-cytokine biologic and/or targeted synthetic therapy combination in spondyloarthritis: a narrative review. Are we missing the opportunity for higher remission rates?脊柱关节炎中双重抗细胞因子生物制剂和/或靶向合成疗法联合应用：一项叙述性综述。我们是否错失了实现更高缓解率的机会？
Front Med (Lausanne). 2025 Jun 3;12:1576411. doi: 10.3389/fmed.2025.1576411. eCollection 2025.
2
Dual Therapy in Inflammatory Bowel Disease.炎症性肠病的双重疗法
Biomolecules. 2025 Feb 3;15(2):222. doi: 10.3390/biom15020222.
3
Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.
炎症性肠病双重生物疗法的进展：疗效、安全性及未来方向。
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241309871. doi: 10.1177/17562848241309871. eCollection 2025.
4
Combination treatment of inflammatory bowel disease: Present status and future perspectives.炎症性肠病的联合治疗：现状与未来展望。
World J Gastroenterol. 2024 Apr 21;30(15):2068-2080. doi: 10.3748/wjg.v30.i15.2068.
5
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain.双靶向治疗银屑病关节炎和脊柱关节炎患者：来自西班牙的真实世界多中心经验。
Front Immunol. 2023 Oct 23;14:1283251. doi: 10.3389/fimmu.2023.1283251. eCollection 2023.
6
Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease.生物制剂与新型小分子药物联合用于炎症性肠病的先进治疗方案
Gastroenterol Hepatol (N Y). 2023 May;19(5):251-263.
7
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.双重生物疗法在炎症性肠病治疗中的新作用。
World J Clin Cases. 2023 Apr 26;11(12):2621-2630. doi: 10.12998/wjcc.v11.i12.2621.
8
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.双重靶向治疗部分或无应答炎症性肠病的疗效和安全性：文献系统评价。
Dig Dis Sci. 2023 Jun;68(6):2604-2623. doi: 10.1007/s10620-023-07837-0. Epub 2023 Feb 20.
9
Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.炎症性肠病相关脊柱关节炎：风湿病学中最后一个未被探索的领域。
Mediterr J Rheumatol. 2022 Apr 15;33(Suppl 1):126-136. doi: 10.31138/mjr.33.1.126. eCollection 2022 Mar.
10
Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual.阿达木单抗、乌司奴单抗和甲氨蝶呤三联疗法用于诱导有生物制剂治疗史的中度至重度回结肠型克罗恩病伴上消化道受累患者的缓解。
BMJ Case Rep. 2021 Oct 13;14(10):e243500. doi: 10.1136/bcr-2021-243500.